MIMEDX GROUP INC (MDXG) Stock Fundamental Analysis
NASDAQ:MDXG - Nasdaq - US6024961012 - Common Stock - Currency: USD
Overall MDXG gets a fundamental rating of 5 out of 10. We evaluated MDXG against 553 industry peers in the Biotechnology industry. While MDXG has a great health rating, its profitability is only average at the moment. MDXG has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
MDXG had positive earnings in the past year.
In the past year MDXG had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MDXG reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MDXG reported negative operating cash flow in multiple years.
1.2 Ratios
With an excellent Return On Assets value of 14.86%, MDXG belongs to the best of the industry, outperforming 96.02% of the companies in the same industry.
The Return On Equity of MDXG (19.82%) is better than 96.20% of its industry peers.
MDXG has a better Return On Invested Capital (14.58%) than 96.38% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.86% | ||
| ROE | 19.82% | ||
| ROIC | 14.58% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MDXG's Profit Margin of 11.40% is amongst the best of the industry. MDXG outperforms 93.49% of its industry peers.
MDXG has a Operating Margin of 12.86%. This is amongst the best in the industry. MDXG outperforms 94.21% of its industry peers.
MDXG's Operating Margin has been stable in the last couple of years.
With an excellent Gross Margin value of 81.94%, MDXG belongs to the best of the industry, outperforming 86.08% of the companies in the same industry.
MDXG's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.86% | ||
| PM (TTM) | 11.4% | ||
| GM | 81.94% |
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDXG is still creating some value.
Compared to 1 year ago, MDXG has more shares outstanding
The number of shares outstanding for MDXG has been increased compared to 5 years ago.
The debt/assets ratio for MDXG has been reduced compared to a year ago.
2.2 Solvency
MDXG has an Altman-Z score of 11.54. This indicates that MDXG is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of MDXG (11.54) is better than 88.25% of its industry peers.
The Debt to FCF ratio of MDXG is 0.29, which is an excellent value as it means it would take MDXG, only 0.29 years of fcf income to pay off all of its debts.
MDXG's Debt to FCF ratio of 0.29 is amongst the best of the industry. MDXG outperforms 95.84% of its industry peers.
A Debt/Equity ratio of 0.09 indicates that MDXG is not too dependend on debt financing.
MDXG has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: MDXG underperforms 64.38% of its industry peers.
Although MDXG does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.29 | ||
| Altman-Z | 11.54 |
ROIC/WACC1.49
WACC9.77%
2.3 Liquidity
MDXG has a Current Ratio of 4.70. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Current ratio (4.70) which is in line with its industry peers.
MDXG has a Quick Ratio of 4.13. This indicates that MDXG is financially healthy and has no problem in meeting its short term obligations.
MDXG has a Quick ratio (4.13) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.7 | ||
| Quick Ratio | 4.13 |
3. Growth
3.1 Past
The earnings per share for MDXG have decreased strongly by -54.39% in the last year.
The Revenue has grown by 8.52% in the past year. This is quite good.
Measured over the past years, MDXG shows a small growth in Revenue. The Revenue has been growing by 3.11% on average per year.
EPS 1Y (TTM)-54.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)8.52%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%13.07%
3.2 Future
Based on estimates for the next years, MDXG will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.19% on average per year.
MDXG is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.54% yearly.
EPS Next Y-11.19%
EPS Next 2Y7.74%
EPS Next 3Y8.19%
EPS Next 5YN/A
Revenue Next Year8.51%
Revenue Next 2Y9.96%
Revenue Next 3Y10.14%
Revenue Next 5Y12.54%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 27.54, which means the current valuation is very expensive for MDXG.
Based on the Price/Earnings ratio, MDXG is valued cheaply inside the industry as 93.85% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.82, MDXG is valued at the same level.
MDXG is valuated rather expensively with a Price/Forward Earnings ratio of 21.27.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MDXG indicates a rather cheap valuation: MDXG is cheaper than 92.22% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.21, MDXG is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.54 | ||
| Fwd PE | 21.27 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MDXG is valued cheaply inside the industry as 94.94% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, MDXG is valued cheaper than 94.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.38 | ||
| EV/EBITDA | 18.11 |
4.3 Compensation for Growth
MDXG has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.74%
EPS Next 3Y8.19%
5. Dividend
5.1 Amount
No dividends for MDXG!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
7.16
-0.03 (-0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners70.18%
Inst Owner Change0.25%
Ins Owners1.74%
Ins Owner Change1.15%
Market Cap1.06B
Analysts81.82
Price Target12.24 (70.95%)
Short Float %3.81%
Short Ratio7.65
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-12.48%
Min EPS beat(2)-31.92%
Max EPS beat(2)6.95%
EPS beat(4)3
Avg EPS beat(4)9.74%
Min EPS beat(4)-31.92%
Max EPS beat(4)52.51%
EPS beat(8)7
Avg EPS beat(8)71.29%
EPS beat(12)9
Avg EPS beat(12)45.41%
EPS beat(16)12
Avg EPS beat(16)48.58%
Revenue beat(2)2
Avg Revenue beat(2)1.09%
Min Revenue beat(2)0.32%
Max Revenue beat(2)1.86%
Revenue beat(4)2
Avg Revenue beat(4)-0.5%
Min Revenue beat(4)-3.85%
Max Revenue beat(4)1.86%
Revenue beat(8)6
Avg Revenue beat(8)1.5%
Revenue beat(12)8
Avg Revenue beat(12)1.63%
Revenue beat(16)12
Avg Revenue beat(16)2.9%
PT rev (1m)0%
PT rev (3m)-11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.6%
EPS NY rev (1m)2.02%
EPS NY rev (3m)-8.18%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.3%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 27.54 | ||
| Fwd PE | 21.27 | ||
| P/S | 3 | ||
| P/FCF | 16.38 | ||
| P/OCF | 16.14 | ||
| P/B | 5.22 | ||
| P/tB | 6.14 | ||
| EV/EBITDA | 18.11 |
EPS(TTM)0.26
EY3.63%
EPS(NY)0.34
Fwd EY4.7%
FCF(TTM)0.44
FCFY6.11%
OCF(TTM)0.44
OCFY6.2%
SpS2.39
BVpS1.37
TBVpS1.17
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 14.86% | ||
| ROE | 19.82% | ||
| ROCE | 19.89% | ||
| ROIC | 14.58% | ||
| ROICexc | 27.36% | ||
| ROICexgc | 36.54% | ||
| OM | 12.86% | ||
| PM (TTM) | 11.4% | ||
| GM | 81.94% | ||
| FCFM | 18.33% |
ROA(3y)4.7%
ROA(5y)-7.18%
ROE(3y)1.74%
ROE(5y)-20.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-47.46%
ROICexc growth 3YN/A
ROICexc growth 5Y-21.46%
OM growth 3YN/A
OM growth 5Y-1.06%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.19%
GM growth 5Y-0.67%
F-Score5
Asset Turnover1.3
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 0.29 | ||
| Debt/EBITDA | 0.33 | ||
| Cap/Depr | 11.12% | ||
| Cap/Sales | 0.27% | ||
| Interest Coverage | 27.66 | ||
| Cash Conversion | 121.79% | ||
| Profit Quality | 160.71% | ||
| Current Ratio | 4.7 | ||
| Quick Ratio | 4.13 | ||
| Altman-Z | 11.54 |
F-Score5
WACC9.77%
ROIC/WACC1.49
Cap/Depr(3y)52.31%
Cap/Depr(5y)58.09%
Cap/Sales(3y)0.72%
Cap/Sales(5y)1.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-54.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-11.19%
EPS Next 2Y7.74%
EPS Next 3Y8.19%
EPS Next 5YN/A
Revenue 1Y (TTM)8.52%
Revenue growth 3Y10.5%
Revenue growth 5Y3.11%
Sales Q2Q%13.07%
Revenue Next Year8.51%
Revenue Next 2Y9.96%
Revenue Next 3Y10.14%
Revenue Next 5Y12.54%
EBIT growth 1Y-18.47%
EBIT growth 3YN/A
EBIT growth 5Y2.02%
EBIT Next Year25.32%
EBIT Next 3Y18.64%
EBIT Next 5YN/A
FCF growth 1Y533.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y659.04%
OCF growth 3YN/A
OCF growth 5YN/A